1. Home
  2. GRPN vs ABUS Comparison

GRPN vs ABUS Comparison

Compare GRPN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Groupon Inc.

GRPN

Groupon Inc.

N/A

Current Price

$18.80

Market Cap

1.1B

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.25

Market Cap

887.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRPN
ABUS
Founded
2008
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
887.5M
IPO Year
2011
2008

Fundamental Metrics

Financial Performance
Metric
GRPN
ABUS
Price
$18.80
$4.25
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $28.67
N/A
AVG Volume (30 Days)
994.5K
★ 6.7M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
N/A
★ 0.84
Revenue
★ $2,843,877,000.00
$14,083,000.00
Revenue This Year
$4.06
$1,208.75
Revenue Next Year
$8.03
N/A
P/E Ratio
★ N/A
$4.98
Revenue Growth
N/A
★ 128.21
52 Week Low
$9.17
$3.50
52 Week High
$29.90
$5.45

Technical Indicators

Market Signals
Indicator
GRPN
ABUS
Relative Strength Index (RSI) 43.37 32.80
Support Level $15.92 $4.17
Resistance Level $18.85 $4.57
Average True Range (ATR) 0.97 0.18
MACD -0.07 -0.07
Stochastic Oscillator 25.67 20.00

Price Performance

Historical Comparison
GRPN
ABUS

About GRPN Groupon Inc.

Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: